Efficacy of antigiardial drugs
Efficacy of antigiardial drugs
复制标题
抗贾第药的功效
DOI：
10.1517/14740338.2.6.529
复制
发表时间：
2003
影响因子：
3.1
通讯作者：
J. Upcroft
中科院分区：
文献类型：
--
作者：
Janelle M. Wright;L. Dunn;P. Upcroft;J. Upcroft
鞭毛虫是人类肠道中最常见的寄生虫。寄生虫感染导致人类和动物的肠道疾病，婴儿有患上发育不良综合征的风险。全球贾第虫病的发病率可能高达10亿例。目前推荐的治疗药物包括硝基杂环药物替硝唑、甲硝唑和呋喃唑酮，取代吖啶、奎纳克林和苯并咪唑、阿苯达唑。巴龙霉素也用于某些情况，硝唑尼特被证明是有用的。然而，所有常见的抗心血管药物都有治疗失败的报道，并且在实验室中已经证明了对所有可用药物的耐药性。此外，临床耐药性也有报道，包括甲硝唑和阿苯达唑治疗失败的病例。确定新的抗心血管药物是今后的一个重要考虑因素，但保持现有药物的效用是确保抗心血管药物持续供应的最具成本效益的措施。
The flagellated protozoa Giardia duodenalis is the most commonly detected parasite in the intestinal tract of humans. Infections with the parasite result in diarrhoeal disease in humans and animals, with infants at risk from failureto-thrive syndrome. The incidence of giardiasis worldwide may be as high as 1000 million cases. Current recommended treatments include the nitroheterocyclic drugs tinidazole, metronidazole and furazolidone, the substituted acridine, quinacrine, and the benzimidazole, albendazole. Paromomycin is also used in some situations, and nitazoxanide is proving to be useful. However, treatment failures have been reported with all of the common antigiardial agents, and drug resistance to all available drugs has been demonstrated in the laboratory. In addition, clinical resistance has been reported, including cases where patients failed both metronidazole and albendazole treatments. The identification of new antigiardial drugs is an important consideration for the future, but maintaining the usefulness of the existing drugs is the most cost-effective measure to ensure the continued availability of antigiardial drugs.
人乳中分泌的抗贾第鞭毛虫抗体：对腹泻的保护作用。
影响因子：
8
作者：
Walterspiel,JN;Morrow,AL;Guerrero,ML;Ruiz-Palacios,GM;Pickering,LK
通讯作者：
Pickering,LK